January 25, 2013

Canada's provincial and territorial governments have reached a deal that they said would save money on drugs, but that generic drug makers said had left them "disappointed."

January 17, 2013

The Food and Drug Administration on Wednesday approved Protein Sciences' Flublok, the first trivalent influenza vaccine made using an insect virus (baculovirus) expression system and recombinant DNA technology.

January 17, 2013

Out of more than 200,000 entries, Procter & Gamble named "William R." of Pennsylvania winner of the ultimate sports pack as part of Wild American Flavor Sweepstakes sponsored by Prilosec OTC Wildberry.

January 8, 2013

Abbott Labs has spun off its specialty drug division into a new company called AbbVie, which the new company's leaders heralded Wednesday by ringing the first opening bell of 2013 at the New York Stock Exchange.

December 28, 2012

Emergent BioSolutions announced that it has signed a license agreement with VaxInnate Corporation under which Emergent acquired the exclusive right to manufacture and sell VaxInnate’s pandemic influenza vaccine candidate in the United States.

December 14, 2012

A federal court has ruled in favor of AstraZeneca in a case regarding a cholesterol drug, the company said.

December 7, 2012

The Food and Drug Administration has approved a generic hypertension drug made by Mylan, the company said.

December 6, 2012

Par Pharmaceutical Cos. has contracted with AstraZeneca to distribute an authorized generic version of a drug used to treat high blood pressure, Par said.

November 29, 2012

Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said.

November 14, 2012

The Community Specialty Pharmacy Network has entered a contract with Dara BioSciences to distribute a nonsteroidal anti-estrogen product.

October 29, 2012

Par Pharmaceutical Cos. has bought rights to a generic version of a drug used to treat bipolar disorder and schizophrenia.

October 22, 2012

A deal that would make a specialty pharmacy a distribution source for a new liquid chemotherapy drug may benefit breast cancer patients who have trouble swallowing pills.

October 22, 2012

Sanofi Pasteur announced Monday the presentation of three clinical trials of an experimental influenza vaccine.

October 16, 2012

Perrigo has received tentative approval from the U.S. Food and Drug Administration for its abbreviated new drug application to market over-the-counter omeprazole and sodium bicarbonate capsules in the 20-mg/1,100-mg strength, the store-brand equivalent to Merck's Zegerid OTC.

October 9, 2012

Drug maker Dr. Reddy’s Labs has launched a generic antibiotic drug, the company said. The India-based company announced the launch of amoxicillin tablets, capsules and oral suspension.

September 28, 2012

For the first time in a decade, sales of vaccines declined, Kalorama Information noted in a report released Thursday.

September 20, 2012

Procter & Gamble this week will begin shipping a wildberry-flavored Prilosec OTC.

September 18, 2012

For branded drug makers, the pharmaceutical patent cliff has never loomed higher or steeper. The exposure of so many of the world’s biggest-selling medicines to generic competition for the first time is redefining the pricing model for many of the most widely prescribed classes of pharmaceuticals.

September 11, 2012

Generic drug maker Dr. Reddy's Labs has launched a generic drug for treating high blood pressure, the company said.

September 10, 2012

A drug maker and medical research institute will work together to identify new treatments for bacterial and viral infections.

August 23, 2012

The Food and Drug Administration has approved a generic drug for high blood pressure made by Wockhardt, the Indian drug maker said.

August 17, 2012

Procter & Gamble’s Prilosec OTC still is the best-selling antacid on the market, with more than $252.7 million in annual sales for the 52 weeks ended July 8 across food, drug and mass (excluding Walmart), followed by fellow proton-pump inhibitor Novartis’ Prevacid 24HR ($104.1 million).

August 13, 2012

Pfizer will be the next consumer healthcare company to reach the market with a switched proton-pump inhibitor.

August 9, 2012

AstraZeneca paid $3.2 billion to Amylin Pharmaceuticals Thursday following the latter's acquisition by Bristol-Myers Squibb, AstraZeneca and Bristol said.